June 19, 2023
2 min watch
Save
VIDEO: Liso-cel CAR-T treatment shows strong results in patients with CLL
In this video, Michael Choi, MD, discusses updated data on the results of liso-cel chimeric antigen receptor T-cell treatments on chronic lymphocytic leukemia, presented at ASCO Annual Meeting.
Choi, a hematologist/oncologist at UC San Diego Moores Cancer Center, highlighted the study, which provided promising results from patients treated with lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — also known as liso-cel — and showed durable responses among patients with CLL.
“I don’t think there was a single progression event in that group, or at least very few,” Choi said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Choi reports receiving research funding for his institution from AbbVie, AstraZeneca, Beigene, Geron, MEI Pharma, Merck, Oncternal Therapeutics, Pharmacyclics, Protagonist Therapeutics and VelosBio, and noncompensated consulting for AbbVie.
Read more about